Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced inducement equity awards granted on March 1, 2026. The company granted options to purchase up to 81,600 shares of common stock to three new employees under its 2023 Inducement Plan.

The options vest over four years: 25% after one year, then 1/48th monthly for 36 months, subject to continued service.

Key Figures

Inducement options: 81,600 shares New employees: 3 employees Vesting period: 4 years +3 more

6 metrics

Inducement options 81,600 shares Options granted to three new employees on March 1, 2026

New employees 3 employees Recipients of inducement awards under 2023 Inducement Plan

Vesting period 4 years Stock options vest over four years

Cliff vesting 25% Portion vesting at one-year anniversary of vesting commencement

Monthly vesting fraction 1/48th Remaining shares vest monthly over the next 36 months

Monthly vesting term 36 months Post-cliff vesting period for remaining option shares

Market Reality Check

Price: $21.40 Vol: Volume 1,176,115 is sligh...

normal vol

$21.40 Last Close

Volume Volume 1,176,115 is slightly below the 20-day average of 1,233,652 (relative volume 0.95x). normal

Technical Shares at $21.40 trade above the 200-day MA of $15.61 and are 5.85% below the 52-week high of $22.73.

Peers on Argus

SNDX fell 3.34% while peers were mixed: BHVN dropped 6.74%, ARDX -1.89%, VRDN -0...

1 Down

SNDX fell 3.34% while peers were mixed: BHVN dropped 6.74%, ARDX -1.89%, VRDN -0.37%, VERA was nearly flat and TRML was unchanged. Momentum scanners only flagged BHVN moving down, suggesting today’s action in SNDX is more stock-specific than broad sector rotation.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and update	Positive	+5.0%	Q4 and FY2025 revenue growth plus business update and cash position.
Feb 23	Investor conferences	Neutral	+1.1%	Announcement of participation in several March 2026 investor conferences.
Feb 19	Earnings date set	Neutral	+1.9%	Scheduled Q4 and FY2025 results release and related conference call.
Feb 05	Biotech summit talk	Neutral	-1.4%	CEO fireside chat at a 2026 Guggenheim biotech summit.
Feb 04	Inducement grants	Neutral	-1.4%	Inducement option grants for new employees under 2023 Inducement Plan.

Pattern Detected

Recent SNDX news—earnings, conference participation, and prior inducement grants—has generally been followed by modestly positive or small-magnitude price moves, with no clear pattern of selling on routine corporate updates.

Recent Company History

Over the past month, Syndax reported strong Q4 and FY2025 results, with revenue of $68.7M in Q4 and $172.4M for 2025, supported by Revuforj and Niktimvo sales and year-end cash of $394.1M. The stock rose 5.03% after this earnings report. Earlier, the company announced multiple investor conference appearances and its earnings date, which led to small gains. A prior inducement grant on February 1, 2026 coincided with a modest -1.37% move, indicating such awards have not driven large reactions historically.

Market Pulse Summary

This announcement details inducement stock option grants for three new employees covering up to 81,6...

Analysis

This announcement details inducement stock option grants for three new employees covering up to 81,600 shares under the 2023 Inducement Plan, vesting over four years with a standard 25% one-year cliff and monthly vesting thereafter. It does not alter Syndax’s recent fundamentals, which included $68.7M in Q4 2025 revenue and $394.1M in cash. Investors may monitor future filings and updates on Revuforj and Niktimvo commercialization for more material catalysts.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, stock options

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"the Company granted inducement awards to purchase up to 81,600 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

stock options financial

"The stock options will vest over four years, with 25% of the underlying"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. Not financial advice.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What inducement awards did Syndax (SNDX) grant on March 1, 2026?

Syndax granted inducement stock options to purchase up to 81,600 shares to three new employees. According to Syndax, grants were made under the company’s 2023 Inducement Plan and include standard four-year vesting with a one-year cliff and monthly vesting thereafter.

How do the Syndax (SNDX) inducement options vest and when do they begin vesting?

The options vest over four years with a one-year cliff then monthly vesting. According to Syndax, 25% vests on the one-year anniversary, then 1/48th of the underlying shares vest monthly for the remaining 36 months, subject to continued employment.

How many employees received Syndax (SNDX) inducement awards and under which plan?

Three new employees received inducement awards under the company’s 2023 Inducement Plan. According to Syndax, the grants on March 1, 2026, total up to 81,600 optioned shares allocated among those hires.

Do Syndax (SNDX) inducement grants cause immediate dilution for shareholders?

The grants create potential future dilution if options are exercised, but they do not dilute outstanding shares immediately. According to Syndax, these are options subject to vesting and exercise events, so actual dilution depends on future exercises and timing.

What should investors know about the financial impact of Syndax (SNDX) inducement awards?

The announcement discloses 81,600 optioned shares granted, but no exercise price or immediate cash impact. According to Syndax, vesting is service‑based over four years, so material financial effects depend on future exercises and any reporting of share count changes.